Table 2.

Positive¹ autoantibodies in the two treatment groups before, during and 12 mo after treatment

Group		Before treatment			During treatment			After treatment
	n	LKM2	SMA3	ANA4	LKM2	SMA3	ANA4	LKM2	SMA3	ANA4
IFN-monotherapy	21	1	0	0	2	0	2	1	1	2
IFN /ribavirin-combined treatment	18	0	0	2	0	2	1	0	0	0
Total	39	1	0	2	2	2	3	1	1	2

¹Antibody titer was considered positive at values ≥ 1:40;

²Liver kidney microsomal antibody;

³Anti-smooth muscle antibody;

⁴Antinuclear antibody.